The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10180 malaria professionals are enjoying the free benefits of MalariaWorld today

Dihydroartemisinin-Piperaquine

In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene

December 3, 2013 - 10:41 -- Open Access
Author(s): 
Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, Cren J, Taudon N, Rogier C, Parzy D, Pradines B
Reference: 
Malaria Journal 2013, 12 :431 (25 November 2013)
MalariaWorld

The present work demonstrates that there was no cross-resistance between piperaquine and chloroquine among 280 P. falciparum isolates and that piperaquine susceptibility is not associated with pfcrt, the gene involved in chloroquine resistance.

Medical Treatment: 

Brief Report: Increased Risk of Early Vomiting among Infants and Young Children Treated with Dihydroartemisinin-Piperaquine Compared with Artemether-Lumefantrine for Uncomplicated Malaria

October 4, 2010 - 12:25 -- Patrick Sampao
Author(s): 
Darren Creek, Victor Bigira, Emmanuel Arinaitwe, Humphrey Wanzira, Abel Kakuru, Jordan Tappero, Moses R. Kamya, Grant Dorsey, AND Taylor G. Sandison
Reference: 
Am J Trop Med Hyg, Oct 2010; 83: 873 - 875.

We used data from a randomized control trial in rural Uganda to compare the risk of early vomiting (within one hour of dosing) for children 6–24 months of age randomized to receive DP (n = 240) or AL (n = 228) for treatment of uncomplicated malaria.

Person: 
Medical Condition: 

Open Access | Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial

April 22, 2010 - 13:34 -- Kabogo Ndegwa
Author(s): 
Awab G, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee S, Day NP, Singhasivanon P, White NJ, Kaker F
Reference: 
Malaria Journal 2010, 9:105 (21 April 2010)

Chloroquine remains an efficacious treatment for the treatment of vivax malaria in Afghanistan. In a setting where radical therapy cannot be administered, dihydroartemisinin-piperaquine provides additional benefit in terms of post-treatment prophylaxis, reducing the incidence of recurrence from 4-8 weeks after treatment. Trial Registration The trial was registered at ClinicalTrials.gov under identifier NCT00682578.

Country: 
Medical Condition: 

Open Access | Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

December 8, 2009 - 11:55 -- Ingeborg van Schayk
Author(s): 
Shereen Katrak, Anne Gasasira, Emmanuel Arinaitwe, Abel Kakuru, Humphrey Wanzira, Victor Bigira, Taylor G Sandison, Jaco Homsy, Jordan W Tappero, Moses R Kamya, Grant Dorsey
Reference: 
Malaria Journal 2009, 8:272 (30 November 2009)

Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children.

Person: 
Medical Condition: 

Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial

December 7, 2009 - 13:33 -- Ingeborg van Schayk
Author(s): 
Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, et al.
Reference: 
PLoS ONE 4(11): e7871

Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children.

Person: 
Medical Condition: 
Subscribe to RSS - Dihydroartemisinin-Piperaquine